Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Micallef, Ivana N. [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Klein, L. M. [VerfasserIn]   i
 Marulkar, S. [VerfasserIn]   i
 Gandhi, P. J. [VerfasserIn]   i
 McSweeney, P. A. [VerfasserIn]   i
Titel:Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
Verf.angabe:I.N.M. Micallef, A.D. Ho, L.M. Klein, S. Marulkar, P.J. Gandhi and P.A. McSweeney
Jahr:2011
Umfang:6 S.
Fussnoten:published online 17 May 2010 ; Gesehen am 19.08.2022
Titel Quelle:Enthalten in: Bone marrow transplantation
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2011
Band/Heft Quelle:46(2011), 3, Seite 350-355
ISSN Quelle:1476-5365
Abstract:Lenalidomide and other new agents have considerable activity in multiple myeloma (MM) and have changed the landscape of treatment. Data suggest that lenalidomide therapy before autologous hematopoietic stem cell transplantation has a detrimental effect on stem cell mobilization. This retrospective study examined the efficacy of plerixafor in combination with G-CSF among patients with MM previously treated with lenalidomide (median, 4 cycles; range, 1-20 cycles). Data were analyzed for 60 patients who received plerixafor plus G-CSF for frontline mobilization in a phase 3 clinical trial or an expanded access program (n=20) or for remobilization in a compassionate use program (n=40). The overall median number of CD34+ cells collected was 5.6 × 106 per kg (range, 0.45 × 106-37.2 × 106). The minimum number of CD34+ cells (⩾2 × 106 per kg) was collected from 86.7% of patients in a median of 1 day. This minimum was collected from 100% of patients who underwent frontline mobilization and 80% of patients who underwent remobilization. These data suggest that CD34+ hematopoietic stem cells can be successfully and predictably collected with combination plerixafor plus G-CSF for primary or secondary mobilization in the majority of patients with MM who have been previously treated with lenalidomide.
DOI:doi:10.1038/bmt.2010.118
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1038/bmt.2010.118
 Volltext: https://www.nature.com/articles/bmt2010118
 DOI: https://doi.org/10.1038/bmt.2010.118
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Biological therapy
 Clinical pharmacology
 Myeloma
K10plus-PPN:1814726454
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68955652   QR-Code
zum Seitenanfang